Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
Fierce Pharma4d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Bristol Myers says over 50% responded to Sotyktu in psoriatic arthritis trial
Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.
Bristol Myers announces data from Phase 3 POETYK PsA-2
Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...
BioSpace4d
J&J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Yahoo Finance26d
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) trial of its drug candidate Sotyktu (deucravacitinib) for plaque ...
Fierce Biotech4d
J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
Healio11d
New 5-year data showcase Sotyktu’s long-term efficacy, safety for plaque psoriasis
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults ...